Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 4;12(5):2045.
doi: 10.3390/jcm12052045.

Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options

Jérôme Martineau  1 , Solange N Walz  1 , Matteo Scampa  1 , Salvatore Giordano  2 , Daniel F Kalbermatten  1 , Carlo M Oranges  1
Affiliations

Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options

Jérôme Martineau et al. J Clin Med. .

Abstract

(1) Background: Spiradenocarcinoma is an extremely rare malignant adnexal tumor and there are only few studies on survival outcomes. Our aim was to perform an analysis of the demographic and pathological characteristics, treatment patterns, and survival outcomes of patients affected by spiradenocarcinoma. (2) Methods: The Surveillance, Epidemiology, and End Results program database of the National Cancer Institute was searched for all cases of spiradenocarcinoma diagnosed between 2000 and 2019. This database is considered representative of the US population. Demographic, pathological, and treatment variables were retrieved. Overall and disease-specific survival were computed according to the different variables. (3) Results: 90 cases of spiradenocarcinoma (47 females, 43 males) were identified. Mean age at diagnosis was 62.8 years. Regional and distant disease at diagnosis were rare, occurring in 2.2% and 3.3% of cases, respectively. Surgery alone was the most frequent treatment (87.8%), followed by a combination of surgery and radiotherapy (3.3%) and radiation therapy only (1.1%). Five-year overall survival was 76.2% and five-year disease-specific survival was 95.7%. (4) Conclusions: Spiradenocarcinoma equally affects males and females. Regional and distant invasion rates are low. Disease-specific mortality is low and is probably overestimated in the literature. Surgical excision remains the main form of treatment.

Keywords: SEER; adnexal tumor; eccrine; epidemiology; malignant; skin; spiradenocarcinoma; spiradenoma; survival; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Survival distribution according to age and sex.
Figure 2
Figure 2
Survival distribution according to disease stage and treatment modalities.
See this image and copyright information in PMC

References

    1. Ribeiro-Silva A., Shaletich C., Careta R.S., Kazava D.K., Siqueira M.C., Ponton F. Spiradenocarcinoma of the Breast Arising in a Long-Standing Spiradenoma. Ann. Diagn. Pathol. 2004;8:162–166. doi: 10.1016/j.anndiagpath.2004.03.007. - DOI - PubMed
    1. Tanese K., Sato T., Ishiko A. Malignant Eccrine Spiradenoma: Case Report and Review of the Literature, Including 15 Japanese Cases. Clin. Exp. Dermatol. 2010;35:51–55. doi: 10.1111/j.1365-2230.2008.03072.x. - DOI - PubMed
    1. Staiger R.D., Helmchen B., Papet C., Mattiello D., Zingg U. Spiradenocarcinoma: A Comprehensive Data Review. Am. J. Dermatopathol. 2017;39:715–725. doi: 10.1097/DAD.0000000000000910. - DOI - PubMed
    1. Andreoli M.T., Itani K.M.F. Malignant Eccrine Spiradenoma: A Meta-Analysis of Reported Cases. Am. J. Surg. 2011;201:695–699. doi: 10.1016/j.amjsurg.2010.04.015. - DOI - PubMed
    1. Dabska M. On malignant transformation of eccrine spiradenoma. Nowotwory. 1971;21:37–45. - PubMed

LinkOut - more resources